ePoster presentations

Abstract reference	
A. Pharmaceutical policy and administration	
100	**Use of medical services among individuals at risk of developing diabetes identified by the Japanese specific health checkup program** Manabu Akazawa, Meiji Pharmaceutical University, Japan
101	**Analysis of factors related to not accessed to Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus** Nonthanit Chaimongkol, The Maharaj Nakorn Chiang Mai Hospital, Thailand
102	**Effectiveness of polypharmacy reduction policy in Japan: Nationwide retrospective observational study** Takehiro Ishida, Teikyo University, Japan
103	**Affordability of cardiovascular medicines in Armenia** Irina Kazaryan, Yerevan State Medical University, Armenia
104	**Evaluation of the national system of pharmacovigilance in Armenia** Irina Kazaryan, Yerevan State Medical University, Armenia
105	**Comparison of assessment results for Periodic Safety Update Report among the European Union, Korea, the United States, and Japan** Seung-Mi Lee, Daegu Catholic University, Korea
106	**The impact of clinical pharmacist interventions on intravenous administration of antimicrobials by nurses** Akshay Nidha, St.Joseph's College, India
107	**Trend analysis of prescription patterns of psychotropic drugs for elderly patients in Japan: A nationwide population-based study** Jinsang Park, International University of Health and Welfare, Japan
108	**Can external control studies supplement single-arm trial data as part of regulatory, reimbursement and HTA submissions in Asian countries?** Nancy Schoenherr, Merck Healthcare KgaA, Germany
109	**Comparison between comparison group of CASPIAN trial and its reproduction by Medicare 5% sample data** Midori Tateyama, Milliman. Inc, Japan
110	**Impact of COVID-19 Pandemic on medicine supply chain: Experiences of community pharmacists** Girish Thunga, Manipal Academy of Higher Education, India
B. Pharmacoepidemiology and Pharmacovigilance research methods	
111	**Clomiphene Citrate and associated risk of blindness** Abdulaziz Alakeel, Saudi Food and Drug Authority, Saudi Arabia
112	**Adverse drug reactions to first-line anti-tuberculosis drugs and their impact on quality of life in tuberculosis patients** Jeong-Hee Choi, Hallym University College of Medicine, Korea
113	**Exploring measurement issues with the proportion of days covered method used to calculate adherence to cardiovascular medicines: A scoping review** Lachlan L. Dalli, Monash University, Australia
114	**Mortality associated with carbapenem for patients with Carbapenemase-Producing Enterobacteriaceae colonization: A population-based cohort study** Min Fan, University of Hong Kong, Hong Kong
115	**A disproportionality analysis of spontaneous adverse event reports for diabetes insipidus attributed to sevoflurane to FDA Adverse Events Reporting System** Akhil T Jacob, Oxbridge College of Pharmacy, India
116	**Unravelling signals pertinent to citalopram induced hepatic steatosis-a disproportionality analysis in FAERS Database validated through cutting-edge bio-informatics and insilico techniques** Siyad KV, M.S. Ramaiah University of Applied Sciences, India

ePoster presentations

B. Pharmacoepidemiology and Pharmacovigilance research methods	
117	**Adverse drug event surveillance system for common people: Effective utilization of a WhatsApp based drug information platform** Jose J Kochuparambil, St.Joseph's College, India
118	**Indirect cost and utility associated with persistence to treatment in patients with acute coronary syndrome after percutaneous coronary intervention** Erna Kristin, Universitas Gadjah Mada, Indonesia
119	**Comparative risk of arterial thromboembolic events between aflibercept and ranibizumab in patients with Maculopathy** Wan-Ju Annabelle Lee, Chi Mei Medical Center, Taiwan
120	**COVID-19 and post COVID-19 symptoms as adverse events of Amphotericin B: A chronicle with FDA adverse event reporting system (FAERS).** Eswaran Maheswari, M.S. Ramaiah University of Applied Sciences, India
121	**Drug induced mucormycosis reports: A pharmacovigilance study employing FDA Adverse Event Reporting System (FAERS)** Eswaran Maheswari, M.S. Ramaiah University of Applied Sciences, India
122	**Investigation of adverse events reported for sennosides through FDA Adverse Event Reporting System (FAERS)** Eswaran Maheswari, M.S. Ramaiah University of Applied Sciences, India
123	**Validating an approach to reduce immeasurable time bias in cohort studies: A real-world example and Monte Carlo simulation study** In-Sun Oh, Sungkyunkwan University, Korea
124	**Cefaclor-induced hypersensitivity: Differences in the incidence of anaphylaxis relative to other 2nd and 3rd cephalosporins** Hyo-In Rhyou, Sungkyunkwan University/Samsung Changwon Hospital, Korea
125	**Recurrent pregnancy loss and incidence of thrombotic diseases: A retrospective cohort study using large claim database** Sachiko Tanaka, Kyoto University, Japan
126	**Antipsychotics and other risk factors of mortality in patients with delirium** Daniel Hsiang-Te Tsai, National Cheng Kung University, Taiwan
127	**Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in frail people with diabetes** Stephen Wood, Monash University, Australia
128	**Comparison of methods to estimate diabetes-related cost using claims data in China** Zheng Yin, IQVIA, China
129	**Patient-reported Outcome Measures (PROMs) utilization in clinical trials and real-world studies of psoriasis in China: A literature review** Zheng Yin, IQVIA, China
130	**The design considerations for disease registry studies in China** Zheng Yin, IQVIA, China
131	**Trajectories of severity pattern among patients with systemic lupus erythematosus in Korea** Seung-Hun You, Chung-Ang University, Korea
132	**Assessing the performance of physician's prescribing preference as an instrumental variable in comparative effectiveness research with moderate sample sizes** Lisong Zhang, University of Glasgow, United Kingdom

ACPE 2021
ISPE's 13th Asian Conference on Pharmacoepidemiology and
28th Conference of Korean Society for Pharmacoepidemiology and Risk Management
Oct. 13-15, 2021 | COEX, Seoul, Korea
www.acpe2021.org

ePoster presentations

	C. Drug safety risk monitoring, evaluation and prevention
133	**Safety signal of dulaglutide and the risk of arthralgia: Evidence from pharmacovigilance data** Abdulaziz Alakeel, Saudi Food and Drug Authority, Saudi Arabia
134	**Non-vitamin K-dependent oral anticoagulants versus warfarin for atrial fibrillation in morbid obese patients** Monirah Albabtain, Prince Sultan Cardiac Center, Saudi Arabia
135	**Pfizer-Biontech vaccine associated with myocardial infarction as adverse events- signal review** Abdulrahman Alomair, Saudi Food and Drug Authority, Saudi Arabia
136	**Experience of COVID-19 Vaccine use and evaluate side effect in Maioli County** Ching Yu Chang, Da Chien Hospital, Taiwan
137	**Risk of vascular adverse events associated with multiple myeloma treatments in Taiwan: A nested case control study** Mei Tsen Chen, National Taiwan University, Taiwan
138	**Signal detection of co-administration of MMR vaccine with other vaccines** Haerin Cho, Ewha Womans University, Korea
139	**Current state of adverse event reports concerned with age-contraindicated drugs on Korea Pharmaceutical Association Database** Eunyoung Choi, Sungkyunkwan University, Korea
140	**Signal detection of drospirenone-containing oral contraceptives using the Korea Adverse Event Reporting System Database, 2008–2017** Ahhyung Choi, Sungkyunkwan University, Korea
141	**Early safety monitoring of COVID-19 vaccines in elderly over 75** Yun Jae Han, National Medical Center, Korea
143	**Trends and factors in relation to metformin related adverse drug reactions in older adults in Jiangsu Province of China** Yiwen Hua, Southeast University, China
144	**Development of risk prediction model for hypocalcemia in bone metastasis patients treated with denosumab plus natural vitamin D/Ca supplement** Keisuke Ikegami, Keio University, Japan
145	**Cancer risk associated with use of valsartan in Korea: A nationwide cohort study** Ha-Lim Jeon, Sungkyunkwan University, Korea
146	**Relationship between the early initiation of insulin treatment and incidence of diabetic complications in type 2 diabetes in Korea** Ha-Lim Jeon, Sungkyunkwan University, Korea
147	**Knowledge of community pharmacists in the Kathmandu Valley, Nepal about the risks associated with medication use during pregnancy** Sajala Kafle, KIST Medical College, Nepal
148	**Establishment of severance contrast media safety and management office** Sung-Ryeol Kim, Yongin Severance Hospital, Yonsei University College of Medicine, Korea
149	**The status of collection and provision in post-marketing drug adverse event reports in the Republic of Korea** Dahye Kim, Korea Institute of Drug Safety and Risk Management, Korea
150	**An active surveillance study to trace the risk factors associated with adverse drug reactions in COVID-19 treatment** Jose J Kochuparambil, St.Joseph's College, India
151	**Osimertinib-associated pulmonary embolism: Results from serious adverse event review system in the Republic of Korea** Jeong Yoon Kwon, Korea Institute of Drug Safety and Risk Management, Korea

ACPE 2021
ISPE's 13th Asian Conference on Pharmacoepidemiology and
28th Conference of Korean Society for Pharmacoepidemiology and Risk Management
Oct. 13-15, 2021 | COEX, Seoul, Korea
www.acpe2021.org

ePoster presentations

C. Drug safety risk monitoring, evaluation and prevention	
152	**Adverse Events Following Immunization (AEFI) of COVID-19 vaccine in a Province of Thailand** Apichart Laithong, Surin Provincial Health Office, Thailand
153	**Risk factors of adverse reactions following preventive treatment for latent tuberculosis infection in household contacts of active tuberculosis** Jae-Eun Lee, Chung-Ang University, Korea
154	**Signal Detection of Adverse Events of piperacillin/tazobactam using the Korea Adverse Event Reporting System (KAERS) Database** Huieon Lee, Ewha Womans University, Korea
155	**Skin test based strategy for selecting alternative iodinated contrast media in patients with hypersensitivity reaction: A prospective confirmative study** Ji-Hyang Lee, Asan Medical Center, Korea
156	**Korean Medicinal Narcotics exclusive monitoring system using Real World Data reported on NIMS.** Chang-yeob Lee, Korea Institute of Drug Safety and Risk Management, Korea
157	**Signal detection of rotavirus vaccine adverse events using the Korea Adverse Event Reporting System Database** Eunsun Lim, Ewha Womans University, Korea
158	**Cefepime-induced neurotoxicity: A retrospective cohort study in a tertiary healthcare facility** Sonal Sekhar Miraj, Manipal Academy of Higher Education, India
159	**Drug-related problems of patients in primary health care institutions: A systematic review** Xiaofeng Ni, West China Second University Hospital, Sichuan University, China
160	**Comparison of Enhanced Safety Monitoring for COVID-19 Vaccine between United States, United Kingdom, Canada, Australia and Korea** Sewon Park, Chung-Ang University, Korea
161	**An analysis of prescription patterns and occurrence of cardiac disorders in Hydroxychloroquine users in Korea** Nayeong Son, Korea Institute of Drug Safety and Risk Management, Korea
162	**Detecting adverse drug events with the use of Protamine as a trigger tool** Nutjaree Suttitong, Maharaj Nakorn Chaing Mai Hospital, Thailand
163	**Efficacy and safety of inhaled corticosteroid containing combinations in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis** Christy Thomas, National Institute of Pharmaceutical Education and Research (NIPER), India
164	**Detecting drug-drug interaction signal of concomitant use of warfarin and statin using Korea Adverse Event Reporting System Database** Heehyun Won, Ewha Womans University, Korea
165	**Cisplatin-induced nephrotoxicity in childhood cancer: Comparison between two countries** Zulfan Zazuli, Bandung Institute of Technology, Indonesia
D. Pharmacogenomics research and drug safety	
166	**Ustekinumab use associated with vasculitis as Adverse Events - Signal Review** Abdulrahman Alomair, Saudi Food and Drug Authority, Saudi Arabia
167	**Identification of therapeutic potential of Ginsenosides against the Autism spectrum disorder by bioinformatics interlaced with in-silico techniques** Gouri Nair, FPH, MSRUAS, India
168	**The association between HLA Class II Alleles and ICM Anaphylaxis** Ga-Yoon Park, Seoul National University Hospital, Korea

ACPE 2021

ISPE's 13th Asian Conference on Pharmacoepidemiology and
28th Conference of Korean Society for Pharmacoepidemiology and Risk Management

www.acpe2021.org

Oct. 13-15, 2021 | COEX, Seoul, Korea

ePoster presentations

E. Evidence-based medicine	
169	**Beta-agonists maintenance therapy to prevent perinatal mortality in preterm labor: A network meta-analysis** Win Yee Choo, Kaohsiung Medical University, Taiwan
170	**Physician's attitude towards Clinical Pharmacists Advice on the Rational Prescribing of Antibiotics.** Aleena Issac, Nirmala College of Pharmacy, India
171	**A big data analysis of perioperative transfusions and risk factor in autologous breast reconstruction** Hee-Jin Kim, Ewha Womans University, Korea
172	**The prediction of adverse outcomes in older patients with COVID-19 using hospital frailty risk score** Mi-Sook Kim, Seoul National University Hospital, Korea
173	**The Influence of diabetic history in the prognosis of hospitalized COVID-19 Patients - A prospective observational study** Jose J Kochuparambil, St.Joseph's College, India
174	**Real-world Evidence of prognosis in the special population of HCV-coinfected with HBV patients receiving direct-acting antiviral agents** Pei-Chin Lin, Kaohsiung Veterans General Hospital, Taiwan
175	**Risk of fracture with GLP-1 RAs, DPP-4i, or SGLT-2i for type 2 diabetes mellitus: A systematic review and network meta-analysis** Fengqi Liu, Peking University, China
176	**Association between Vitamin E intake and risk of prostate cancer: A meta-analysis involving 6,00,954 subjects** Muhammed Rashid, Manipal Academy of Higher Education, Indi
177	**Efficacy and safety of corticosteroids in Acute Respiratory Distress Syndrome: A systematic review of meta-analyses** Muhammed Rashid, Manipal Academy of Higher Education, India
178	**Global prevalence of hyperuricemia among chronic kidney disease patients - a systematic review and meta-analysis** Ishfaq Rashid, National Institute of Pharmaceutical Education and Research (NIPER), India
179	**Efficacy of antifungal therapy in the management of fungal co-infections in COVID-19 patients: A systematic review and meta-analysis** Atiqulla Shariff, JSS Academy of Higher Education and Research, India
180	**Adverse drug reactions of GLP-1 agonists: A systematic review of descriptive studies** Rashmi Shetty, Manipal Academy of Higher Education, India
181	**Quality assessment of randomized controlled trials and observational studies published on COVID-19 in 2020** Krishna Undela, National Institute of Pharmaceutical Education and Research (NIPER), India
182	**Comparative efficacy and safety of treatment regimens for advanced, recurrent or metastatic endometrial cancer: A systematic review** Snehapriya Yeddala, MCPHS University, United States
F. Evidence-based pharmacy	
183	**Evaluation of practice on antimicrobial medicines dispensing from community pharmacies** Anahit Amirkhanyan, Yerevan State Medical University, Armenia
184	**Clinical outcomes of gestational age based parenteral nutrition initiation in very low birth weight preterm neonates – a pharmacist's purview** Vanitha Rani Nagasubramanian, Sri Ramachandra Institute of Higher Education and Research, India
185	**A point prevalence survey of antimicrobial utilisation patterns and quality indices amongst hospitals in South Africa; findings and implications** Phumzile Skosana, Sefako Makgatho Health Sciences University, South Africa

ePoster presentations

G. Drug utilization evaluation studies	
186	**Assessing the circumstances of poisoning and antidote therapy in a tertiary care teaching hospital** Shraavani Akundi, JSS Academy of Higher Education and Research, India
187	**Adherence and associated factors of treatment regimen in drug-susceptible tuberculosis patients** Sungho Bea, Sungkyunkwan University, Korea
188	**Sub-optimal use of evidence-based medical therapy in chronic limb-threatening ischemia patients undergoing lower-limb revascularization in Singapore** Sze Ling Chan, SingHealth, Singapore
189	**Treatment escalation among steroid dependent patients in inflammatory bowel disease: Before and after approved policy on biologicals** Nai-Yu Chen, National Cheng Kung University, Taiwan
190	**Nationwide patterns of prescribing contraindicated drug-drug interaction pairs in Korea** Wonbin Choi, Chung-Ang Univerisity, Korea
191	**Pregnancy outcomes of women on antiretroviral therapy in Jos University Teaching Hospital: A retrospective study** Maxwell Dapar, University of Jos, Nigeria
192	**Influencing factors for medication in patients with mental disorders in middle-aged-older Chinese: Results from Charls** Jingnan Feng, Peking University, China
193	**Effect of drug subsidy policy on empagliflozin utilisation in Singapore: An interrupted time series analysis** Winnie Foo, Agency for Care Effectiveness, Ministry of Health, Singapore
194	**Evaluation of antimicrobial use and its impact in a private and public hospital: A prospective comparative from in India** Aleena Issac, Nirmala College of Pharmacy, India
195	**Outcomes and adverse events of methylphenidate treatment in pediatric patients: A cross-sectional study** Penkarn Kanjanarat, Faculty of Pharmacy, Thailand
196	**Drug use evaluation on Favipiravir for COVID-19 patients, Hua Hin Hospital** Mattiga Kulee, Hua-Hin Hospital, Thailand
197	**Impact of guideline on prescribing practice in antipsychotics in patients with dementia** Miriam Leung, University of Hong Kong, Hong Kong
198	**Drug utilization review on antimicrobial agents in Ent Department** Jeet Bahadur Moktan, Adichunchanagiri University, India
199	**Evaluation of empirical antibiotics for community acquired Pneumonia in a hospital in Indonesia** Dyah Aryani Perwitasari, Universitas Ahmad Dahlan, Indonesia
200	**Pharmacoepidemiology of antibacterials use by Russian hospitals during the period 2009-2019** Dariya Savintseva, Sechenov University, Russian Federation
201	**Evaluation of epidemiology in poisoned patients and cost analysis of antidotes at a tertiary care hospital** Anjana Urath, JSS Academy of Higher Education and Research, India
202	**Utilization pattern of anti-thrombotic agents in Peripheral Artery Disease patients with Chronic Kidney Disease: A nationwide retrospective cohort Study** Jui-Hsien Wang, National Cheng Kung University, Taiwan
203	**Long-term utilization of extended-release methylphenidate among patients with attention-deficit hyperactivity disorder in Asia and North America** Youran Xu, Janssen Research & Development, LLC, China
204	**Evolving trends in consumption of direct oral anticoagulants in 65 countries from 2008 to 2019: Analysis of pharmaceutical sales data** Vincent KC Yan, The University of Hong Kong, Hong Kong

ePoster presentations

H. Rational drug use	
205	**Prescribing antibiotics in children by primary care physicians** Anahit Amirkhanyan, Yerevan State Medical University, Armenia
206	**Oxytetracycline residues in chicken table eggs sold in Gombe, Nigeria are within acceptable levels but may have cumulative effect** Sulayman Balogun, University of Maiduguri, Nigeria
207	**Effect of information provision using video media on patients' knowledge about antibiotics and anti-inflammatory drugs** Thanasit Mangsuk, Chiang Mai University, Thailand
208	**Drug-related problems in prescribing for outpatients in Vietnam** Thang Nguyen, Can Tho University of Medicine and Pharmacy, Viet Nam
209	**Antibiotic prescribing and cost after Implementation of Rationale Drug Use policy in health care settings in Thailand** Watanyoo Prayoonhong, Phimai Hospital, Thailand
210	**Criteria used by professionals for selecting resources of medicines information** Anahit Sevikyan, Yerevan State Medical University, Armenia
211	**The prevalence of inappropriate sale of drugs in grocery stores** Sunisa Thinkeaw, Kapongchaipat Hospital, Thailand
212	**Reference books as sources of information on use of medicines in children** Lusine Vardanyan, Yerevan State Medical University, Armenia
I. Pharmacoepidemiology and traditional medicines	
213	**Real-world evidence of herpes zoster's disease burden and characteristics: A retrospective study in Fuzhou, China** Yang Feng, Xiamen Chazen Biomedical Technology Co., Ltd., China
214	**Trends of polypharmacy in patients living with dementia from 2005 to 2019** Miriam Leung, University of Hong Kong, Hong Kong
215	**Using real world data to investigate the relationship between Chinese herbal medicine decoction pieces and acute kidney injury** Tsung Hsuan Lin, Chi Mei Medical Center/National Cheng Kung University, Taiwan
216	**Incidence of non-alcoholic fatty liver diseases and their associated risk factors among type-2 diabetic population in Telangana, India** Usha Sree Puneem, Sri Ramachandra University, India
217	**Prevalence and characteristics of unsafe health products in community in Chiang Mai, Thailand** Audchara Sansrisawad, Chiang Mai University, Thailand
218	**Use of beta blockers and death from breast cancer in New Zealand breast cancer patients** Oliver Scott, University of Auckland, New Zealand
J. Prevention of medication errors and drug misuse/abuse	
219	**Prescriptions errors and role of pharmacists in ensuring patient safety** Irina Kazaryan, Yerevan State Medical University, Armenia
220	**Effects of pharmacist-based education on drug allergies in hospitalized patients** Cheeratikarn Phithakham, Chiang Mai University, Thailand
221	**Drug-related problems in in-patients in orthopedic wards at a regional hospital** Nichakorn Piriyachananusorn, Uttaradit Hospital, Thailand
222	**Methadone education initiative for ethnic minorities in Northern Thailand** Nannaphat Rungsiwaroj, Thanyarak Chiangmai Hospital, Thailand
223	**Impact of clinical pharmacist collaborative care in identifying and resolving drug related problems in systemic autoimmune disorders patients** Sujit Sah, JSS Academy of Higher Education and Research, India

ePoster presentations

	J. Prevention of medication errors and drug misuse/abuse
224	**Assessment of Clinical Pharmacist Initiated Interventions in a Pediatric Intensive Care Unit** Juny Sebastian, JSS Academy of Higher Education and Research, India
225	**Understanding by patients medicines information presented in patient package inserts** Anahit Sevikyan, Yerevan State Medical University, Armenia
226	**Real world effectiveness of methadone maintenance treatment on the reduction of suicidal attempts in patients with opioid use disorder** Cheng-Chan Shih, National Cheng Kung University, Taiwan
	K. Rare disease and orphan medicines
227	**Incidence and risk factors of steroid-related damage in Korean patients with Systemic lupus erythematosus, compared to general population, 2002-2018** Joo-Hyeon Eom, Graduate School of Chung-Ang University, Korea
228	**Incidence and prevalence of moyamoya disease in urban China: A nationwide population-based study** Yixin Sun, Peking University, China
	L. Post-marketing drug effectiveness and safety evaluation
229	**Pharmacovigilance studies of atenolol among hypertensive patients in Government secondary care hospital of Hyderabad, Pakistan** Mudassar Iqbal Arain, University of Sindh Jamshoro, Pakistan
230	**Real-world effectiveness of lenvatinib and sequential treatment in the patients with hepatocellular carcinoma: Evidence from Taiwan** Chun Ning Chang, Linkou Chang Gung Memorial Hospital, Taiwan
231	**LDL-C Trajectories of statin initiators among patients with diabetes** Miyuki Hsieh, National Cheng Kung University, Taiwan
232	**Delayed cutaneous adverse reactions to ChAdOx1 nCoV-19 vaccine** Sang-Heon Kim, Hanyang University College of Medicine, Korea
233	**Detecting early safety signals for infliximab using machine learning algorithms in the Korea adverse event reporting system** Ju Hwan Kim, Sungkyunkwan University, Korea
234	**Effects of ambroxol on COVID-19 patients: A retrospective cohort study of 1922 patients** Yun Lu, Zhongnan Hospital of Wuhan University, China
235	**Real world effectiveness of immunotherapy in advanced non-small cell lung cancer patients with versus without documented psoriasis or rheumatoid arthritis** Mohsin Shah, University of Pennsylvania, United States
236	**SGLT2 inhibitors and risk of pancreatitis: A disproportionality analysis and systematic review of case reports** Krishna Undela, National Institute of Pharmaceutical Education and Research (NIPER), India
237	**Anticholinergic drugs use and risk of falls in the elderly: A retrospective cohort study** Phar Watcharathanakij, Ubon Ratchathani University, Thailand
238	**Prescription of atypical antipsychotics and the risk of hypothyroidism: A population-based, case-case-time-control study** Bo Ram Yang, Chungnam National University, Korea

ACPE 2021
www.acpe2021.org
ISPE's 13th Asian Conference on Pharmacoepidemiology and
28th Conference of Korean Society for Pharmacoepidemiology and Risk Management
Oct. 13-15, 2021 | COEX, Seoul, Korea

ePoster presentations

M. Prevention and treatment of drug-induced diseases	
239	**Steroid stewardship as a tool to tackle glucocorticoid induced hyperglycemia in COVID -19 patients** Aleena Issac, Nirmala College of Pharmacy, India
240	**Outcomes of 821 desensitization cases performed in a single tertiary hospital** Hyun Hwa Kim, Seoul National University Hospital, Korea
241	**Prevalence of immediate ADR from repetitive administration of iodinated RCM: Effectiveness of premedication and alternative RCM** Sung-Ryeol Kim, Yongin Severance Hospital, Yonsei University College of Medicine, Korea
242	**How to reduce breakthrough response in contrast media re-exposure in patients with contrast media anaphylaxis?** Ga-Yoon Park, Seoul National University Hospital, Korea
243	**Identification of putative drugs for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome using inverse FAERS** Aina Shaju, M.S. Ramaiah University of Applied Sciences, India
N. Other related fields	
244	**Spontaneous reporting of adverse events following COVID-19 Vaccination: First 90 days experience from a hospital in South India** Sheba Baby John, JSS Academy of Higher Education and Research, India
245	**Relationship between Serum 25-Hydroxycholecalciferol status and patients with Polyarthralgia** Tejaswini Baral, Manipal Academy of Higher Education, India
246	**Association between Body Mass Index and short term-outcomes of stroke: Shiga Stroke and Heart Attack Registry** Tserenlkham Byambajav, Shiga University of Medical Science, Japan
247	**How to develop a real-world evidence strategy: Searching for a framework and validating it in cases from US and China** Junqiao Chen, Roche Hong Kong Limited, Hong Kong
248	**Drug-induced hepatotoxicity: An analysis of drug injury relief applications in Taiwan** Mei-Yi Chien, Taiwan Drug Relief Foundation, Taiwan
249	**A widespread failure to disclose: Audit of conflict of interest statements by Australian authors of Recent Clinical Trial Reports** Bennett Holman, Yonsei University, Korea
250	**Practice of face masking among young adults in South India: An online cross-sectional survey** Aleena Issac, Nirmala College of Pharmacy, India
251	**Descriptive analysis of Adverse Drug Reaction in a single hospital: A comparison of health insurance and medical aid patients** Hyesu Jeong, National Medical Center, Korea
252	**Evaluating the Knowledge and practice regarding foot care in diabetes mellitus patients visiting a tertiary care hospital of South India** Jose J Kochuparambil, St.Joseph's College, India
253	**Intra family encouragement in self-management of Type 2 Diabetes: A cross sectional evaluation in the Indian population** Jose J Kochuparambil, St.Joseph's College, India
254	**Risk classification and mortality prediction in patients with community-onset bacteremia: Machine learning derived algorithm** Chun Te Li, National Cheng Kung University, Taiwan
255	**Provision of answers to the poison information queries from public and healthcare practitioners (HCPS) at a tertiary care hospital** Umesh Marappa, JSS Academy of Higher Education and Research, India

ePoster presentations

N. Other related fields

256	**Effects of pharmaceutical care in CKD stage 3-4 patients and patients at risks of CKD at a secondary care hospital** Kanyarat Phromkamdang, Wiang Haeng Hospital, Thailand
257	**Effects of pharmaceutical care in patients with chronic kidney disease at a secondary care hospital** Kanyarat Phromkamdang, Wiang Haeng Hospital, Thailand
258	**Attitudes and opinions of 5th-year pharmacy students toward online OPSE in the COVID-19 era: A preliminary survey** Prompiriya Pitirattanaworranat, Rangsit University, Thailand
259	**Validation of Interview Guide: By adapting interview protocol refinement method** Manasvini Ramakrishnan, Manipal Academy of Higher Education, India
260	**Artificial intelligence in acute respiratory distress syndrome: A systematic review** Muhammed Rashid, Manipal Academy of Higher Education, India
261	**Assessment of public knowledge and attitude towards chronic kidney disease by using a validated questionnaire: A cross-sectional study** Ishfaq Rashid, National Institute of Pharmaceutical Education and Research (NIPER), India
262	**Evaluation on Hand Hygiene Knowledge and behavior among general population - A cross sectional study** Vishal Anand S S, JSS Academy of Higher Education and Research, India
263	**Comparison of drug safety reporting features among East and Southeast Asian countries** Kimie Sai, National Institute of Health Sciences, Japan
264	**Health literacy and awareness For COVID-19 prevention in Asia: A systematic literature review** Akhilesh Vikram Singh, Datta Meghe Institute of Medical Sciences, India
265	**Bariatric surgery for glycemic control in patients with type 2 diabetes mellitus: A systematic review and meta-analysis** Minjung Son, Yonsei University, Korea
266	**Glycemic control of insulin therapy in diabetic patients at a tertiary care hospital** Karuna Sooktong, Thanyarak Chiangmai Hospital, Thailand
267	**Prevalence and factors associated with periodontal disease and dental caries among patients with diabetes mellitus** Krist Suwannarat, Chiang Mai university, Thailand
268	**Recent trends in the incidence and prevalence of inflammatory bowel disease (IBD) in Japan and the US** Michiyo Yamazaki, Johnson & Johnson, United States
269	**Public perception towards expanding role of pharmacist in Sabah and Selangor, Malaysia** Cindra Tri Yuniar, Institut Teknologi Bandung, Indonesia